Pliant Therapeutics (PLRX) HR chief has 7,534 shares sold for tax withholding

Rhea-AI Filing Summary

Pliant Therapeutics Chief Human Resource Officer Lily Cheung reported a sale of company stock under a tax-withholding plan. On January 20, 2026, a company plan sold 7,534 shares of Common Stock on her behalf at a weighted-average price of $1.28 per share, in transactions intended to comply with Rule 10b5-1. The sales were executed between $1.245 and $1.33 over several days to cover withholding taxes tied to the vesting of previously granted restricted stock units.

After these transactions, Cheung beneficially owned 44,847 shares of Pliant Therapeutics Common Stock. This total includes 1,956 shares acquired through an Employee Stock Purchase Plan program, showing she continues to hold a meaningful equity position in the company.

Insider Trade Summary

Net Seller: 7,534 shares ($9,644)

Net Sell 1 txn

Insider Cheung Lily

Role Chief Human Resource Officer

Sold 7,534 shs ($10K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,534	$1.28	$10K

Holdings After Transaction: Common Stock — 44,847 shares (Direct)

Footnotes (1)

1. Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. Includes 1,956 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cheung Lily

(Last) (First) (Middle)

C/O PLIANT THERAPEUTICS, INC.

331 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resource Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		S		7,534	D	$1.28(1)	44,847(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.

2. Includes 1,956 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.

Remarks:

	/s/ Jennifer Woo, attorney-in-fact	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Pliant Therapeutics (PLRX) insider Lily Cheung report in this Form 4?

Lily Cheung, Chief Human Resource Officer of Pliant Therapeutics (PLRX), reported a plan-driven sale of 7,534 shares of Common Stock on January 20, 2026, at a weighted-average price of $1.28 per share, primarily to cover tax withholding on vested restricted stock units.

How many Pliant Therapeutics shares does Lily Cheung hold after the reported transaction?

Following the reported sale, Lily Cheung beneficially owned 44,847 shares of Pliant Therapeutics Common Stock, as disclosed in the Form 4.

Was the PLRX insider sale by Lily Cheung a discretionary trade?

No. The filing states the sale was a nondiscretionary sale by the plan on behalf of the reporting person, intended to satisfy Rule 10b5-1 and to pay withholding taxes related to the vesting of previously granted restricted stock units.

What price range applied to the Pliant Therapeutics shares sold for Lily Cheung?

The Form 4 explains that the sale price per share reflects a weighted average of trades executed between $1.245 and $1.33 over the period from January 20, 2026 through January 22, 2026.

Does Lily Cheung participate in Pliant Therapeutics’ Employee Stock Purchase Plan?

Yes. The filing notes that her holdings include 1,956 shares of Common Stock acquired through an Employee Stock Purchase Plan program.

What is Lily Cheung’s role at Pliant Therapeutics (PLRX)?

According to the Form 4, Lily Cheung is an officer of Pliant Therapeutics, serving as the company’s Chief Human Resource Officer.